Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated

MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN)

MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “ Issuer ” or the “ Company ”) and Syneos Health, Inc. (“ Syneos Health ”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of

Signs Agreement with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology MORRISVILLE, N.C. – August 23, 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with

MORRISVILLE, N.C. – August  10, 2023 – Syneos Health® (Nasdaq:SYNH) a leading fully integrated biopharmaceutical  solutions organization, today announced that it has signed an agreement with Aotearoa Clinical Trials, expanding the Company’s clinical trial capabilities across  a broad range of

  MORRISVILLE, N.C. – August, 8 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has entered into an agreement with University Malaya Medical Centre, expanding the Company’s clinical trial capabilities across a broader

  Japanese Version Chinese Version Company Hires Yunke Song to Drive Commercial Growth in Region MORRISVILLE, N.C., August 3, 2023 – Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today appointed Yunke Song as Managing Director of Deployment

MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through

MORRISVILLE, N.C. – July 31, 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with Optimal Clinical Trials Ltd. The agreement will expand the Company’s clinical trial capabilities across a broad

Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services Environment MORRISVILLE, N.C., July 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of

Company Hires Shigeto Miyamoto to Drive Strategic Commercial and  Digital Priorities for Region   MORRISVILLE, N.C., DATE, 2023 - Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Shigeto Miyamoto as

Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology Expertise MORRISVILLE, N.C., June 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with

Newly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across Organization MORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the

Healthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact MORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that Jennifer

Company Executives Honored for Notable Biopharmaceutical Industry Impact MORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and

Revenue for the first quarter of $1,356.8 million increased 1.5% on a reported basis and increased 2.4% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $713.6 million for the first

Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today

Finance Leader with 30+ Years of Experience, Including 15 Years in Clinical Research Industry MORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Bonello as

Company Recognized for Positive Vaccine Expertise Contributions MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry Excellence Award for

MORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O’Kane as President of Syneos Health Communications — a portfolio of agencies spanning advertising, public relations,

Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences MORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical

Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution MORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker

Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance MORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement

Newly Established Network Will Enable High Quality DCTs & Digital Health Technology Solutions MORRISVILLE, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of a Decentralized

Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $470.1 million for the fourth

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 a.m. ET.

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer

Combined Capabilities Will Help Improve Trial Lifecycles for Patients, Sites & Sponsors MORRISVILLE, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Haystack

Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services NASHVILLE, Tenn. , Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (" Cryoport "), a leading global provider of innovative temperature-controlled

MORRISVILLE, N.C. – January 16, 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, announced that it has entered into a partnership with Clinical Research Malaysia (CRM), expanding the Company’s clinical trial capabilities across a broader

Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions MORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun

Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of Inertia MORRISVILLE, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 13 th annual

Reaffirms Full-Year 2022 Revenue Guidance MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that, effective March 31, 2023, Jason Meggs will transition from his role as Chief

MORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to present at the 41 st Annual J.P.